CHEK2 and breast carcinoma: A frameshift deletion in CHEK2 (rs555607708; MAF = 0.64% (FG), 0.24% (UKB)) that increases breast cancer risk has also been previously implicated in myeloproliferative neoplasms through GWAS18 and lymphoid leukaemia in a candidate variant study19.